Google to pursue new biomarker study; Lantheus Holdings, T2 Biosystems set IPO terms;

> Google ($GOOG) plans to search for biomarkers as part of its new Baseline Study initiative, which will involve the use of Google experimental wearable devices to collect urine, blood, saliva and tears. Story

> Boston University scientists said they've found another potential new biomarker for Alzheimer's disease--variants in the gene PLXNA4--that may point to an increased risk. Story

> Lantheus Holdings, a seller of medical imaging agents used to diagnose cardiovascular diseases, was expected to trigger its IPO this week with a share price range between $12 and $15. Plans calls for raising as much as $125 million. Item

> Molecular diagnostics outfit T2 Biosystems set a price range for its pending IPO of between $15 and $17 per share. Story (reg. req.)

> CareDx said it has generated promising new results demonstrating the utility of its diagnostic technology to screen for symptoms of heart transplant rejection. Release

> Qiagen ($QGEN) and AstraZeneca ($AZN) will co-develop and sell a liquid biopsy-based companion diagnostic to be paired with Iressa, AstraZeneca's targeted treatment for non-small cell lung cancer. Release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.